Regulators on the Verge of Bungling Drug Price Reform, Advocates Say

The starting point for negotiations with drug companies on prescription prices could end up being the too-high prices patients already live with.

by

The American Prospect is nonprofit, reader-funded journalism—and we need your help.

Our reporters dig deep, hold power to account, and explain how policy shapes people’s lives. If you value independent journalism that goes beyond the headlines, now’s the time to support it.

Here’s how you can help:
Donate to power fearless reporting
Subscribe to get our print magazine 6x/year. 

Every dollar funds our in-depth reporting. 


Donate Now. Subscribe here.